Tsung-Ming Shih Selected Research

Nerve Agents

4/2024	Hypothermia as Potential Therapeutic Approach to Attenuating Soman-Induced Seizure, Neuropathology, and Mortality with an Adenosine A1 Receptor Agonist and Body Cooling.
1/2021	Intramuscularly administered A1 adenosine receptor agonists as delayed treatment for organophosphorus nerve agent-induced Status Epilepticus.
6/2016	Evaluation of acetylcholine, seizure activity and neuropathology following high-dose nerve agent exposure and delayed neuroprotective treatment drugs in freely moving rats.
9/2014	Stimulation of central A1 adenosine receptors suppresses seizure and neuropathology in a soman nerve agent seizure rat model.
6/2012	Neuropharmacological specificity of brain structures involved in soman-induced seizures.
12/2011	In vivo microdialysis and electroencephalographic activity in freely moving guinea pigs exposed to organophosphorus nerve agents sarin and VX: analysis of acetylcholine and glutamate.
7/2010	Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs.
3/2010	Changes in extracellular striatal acetylcholine and brain seizure activity following acute exposure to nerve agents in freely moving guinea pigs.
1/2010	Protection against sarin-induced seizures in rats by direct brain microinjection of scopolamine, midazolam or MK-801.
12/2009	Effects of 4-pyridine aldoxime on nerve agent-inhibited acetylcholinesterase activity in guinea pigs.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsung-Ming Shih Research Topics

Disease

12	Seizures (Absence Seizure) 06/2016 - 04/2003
7	Status Epilepticus (Complex Partial Status Epilepticus) 05/2024 - 02/2004
3	Poisoning 09/2014 - 03/2003
3	Coma (Comas) 12/2011 - 01/2007
2	Hypothermia 04/2024 - 08/2019
1	Bradycardia 08/2019
1	Tremor (Tremors) 11/2010
1	Rhinorrhea 12/2009

Drug/Important Bio-Agent (IBA)

15	Nerve AgentsIBA 04/2024 - 03/2003
11	SomanIBA 05/2024 - 04/2003
8	SarinIBA 01/2021 - 03/2003
6	Anticonvulsants (Antiepileptic Drugs)IBA 06/2012 - 04/2003
5	Midazolam (Versed)FDA LinkGeneric 06/2016 - 04/2003
5	Diazepam (Valium)FDA LinkGeneric 07/2010 - 04/2003
4	BenzodiazepinesIBA 06/2012 - 04/2003
4	VX (EDIM)IBA 12/2011 - 04/2003
3	AcetylcholinesteraseIBA 06/2016 - 11/2010
3	Scopolamine (Hyoscine)FDA Link 06/2016 - 01/2007
3	Acetylcholine (Acetylcholine Chloride)FDA Link 06/2016 - 11/2010
3	cyclohexyl methylphosphonofluoridate (cyclosarin)IBA 01/2011 - 04/2003
3	Atropine FDA LinkGeneric 09/2009 - 04/2003
2	Cholinergic Antagonists (Anticholinergics)IBA 06/2012 - 04/2003
2	OximesIBA 01/2010 - 09/2009
2	tabunIBA 01/2007 - 04/2003
1	Organophosphorus CompoundsIBA 05/2024
1	Adenosine A1 ReceptorIBA 04/2024
1	asoxime chloride (H16)IBA 01/2023
1	Purinergic P1 Receptor AgonistsIBA 01/2021
1	nasIBA 01/2021
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 08/2019
1	Topiramate (Topamax)FDA LinkGeneric 06/2016
1	1- (2- amino- 2- carboxyethyl)- 3- (2- carboxybenzyl)pyrimidine- 2,4- dioneIBA 06/2016
1	Clobazam (HR 376)IBA 06/2016
1	Ketamine FDA LinkGeneric 06/2016
1	Pregnanolone (Allopregnanolone)IBA 06/2016
1	Neuroprotective AgentsIBA 06/2016
1	Excitatory Amino Acid AntagonistsIBA 06/2012
1	Excitatory Amino AcidsIBA 06/2012
1	Dizocilpine Maleate (Dizocilpine)IBA 01/2010
1	N-Methylaspartate (NMDA)IBA 01/2010
1	Muscarinic AntagonistsIBA 01/2010
1	fosphenytoin (Cerebyx)FDA LinkGeneric 02/2004
1	P-30 composite resin (P 30)IBA 02/2004
1	Biperiden (Akineton)FDA Link 04/2003
1	Trihexyphenidyl (Artane)FDA LinkGeneric 04/2003

Therapy/Procedure

1	Electrodes (Electrode) 01/2023
1	Treatment Delay 01/2021